• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CD5和INSM1的同时表达可能有助于将腮腺CASTLE与其他具有鳞状细胞表型的原发性肿瘤区分开来。

Simultaneous expression of CD5 and INSM1 may distinguish parotid CASTLE from other primary tumors with a squamous phenotype.

作者信息

Zhang Dan, Wang Chaoshan, Zhang Haorui, Yang Wenmin, Nie Ling

机构信息

Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu Province, China.

Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu Province, China.

出版信息

Ann Diagn Pathol. 2025 Jul 14;79:152531. doi: 10.1016/j.anndiagpath.2025.152531.

DOI:10.1016/j.anndiagpath.2025.152531
PMID:40674896
Abstract

Parotid carcinoma showing thymus-like element (CASTLE) is positive for the immunohistochemical markers CD5 and CD117. However, the specificity of the markers has not been evaluated in parotid tumors with a squamous phenotype. This study aims to validate the efficiency of CD5, CD117, and INSM1 in distinguishing CASTLE from other parotid tumors with a squamous phenotype, including squamous cell carcinoma (SCC, n = 4), lymphoepithelial carcinoma (LEC, n = 5), and pleomorphic adenoma with squamous differentiation (PA-SD, n = 3). The parotid CASTLE exhibited diffusely CD5 membranous positivity (Immunoreactive Score, IRS = 12) and moderate INSM1 nuclear expression (IRS = 6), while SCC, PA-SD, and LEC showed negligible CD5 (IRS ≤ 2) and weak/focal INSM1 (IRS ≤ 3) expression. Although CD117 was diffusely positive in CASTLE, it was moderately to strongly expressed in the LECs (IRS = 9), limiting its diagnostic utility in differential diagnosis. EBER in situ hybridization (ISH) confirmed EBV association in all LECs but not in the CASTLE. In summary, simultaneous CD5 and INSM1 expression may serve as a distinct feature for parotid CASTLE, facilitating differential diagnosis in salivary gland pathology. In addition, EBER ISH remains essential to exclude LEC.

摘要

具有胸腺样成分的腮腺癌(CASTLE)对免疫组化标志物CD5和CD117呈阳性。然而,这些标志物在具有鳞状表型的腮腺肿瘤中的特异性尚未得到评估。本研究旨在验证CD5、CD117和INSM1在区分CASTLE与其他具有鳞状表型的腮腺肿瘤中的有效性,这些肿瘤包括鳞状细胞癌(SCC,n = 4)、淋巴上皮癌(LEC,n = 5)和具有鳞状分化的多形性腺瘤(PA-SD,n = 3)。腮腺CASTLE表现为CD5弥漫性膜阳性(免疫反应评分,IRS = 12)和INSM1中等程度核表达(IRS = 6),而SCC、PA-SD和LEC的CD5表达可忽略不计(IRS≤2),INSM1表达为弱/局灶性(IRS≤3)。尽管CD117在CASTLE中弥漫性阳性,但在LEC中呈中度至强表达(IRS = 9),限制了其在鉴别诊断中的应用。EBER原位杂交(ISH)证实所有LEC中存在EBV关联,但CASTLE中不存在。总之,CD5和INSM1同时表达可能是腮腺CASTLE的一个独特特征,有助于涎腺病理学中的鉴别诊断。此外,EBER ISH对于排除LEC仍然至关重要。

相似文献

1
Simultaneous expression of CD5 and INSM1 may distinguish parotid CASTLE from other primary tumors with a squamous phenotype.CD5和INSM1的同时表达可能有助于将腮腺CASTLE与其他具有鳞状细胞表型的原发性肿瘤区分开来。
Ann Diagn Pathol. 2025 Jul 14;79:152531. doi: 10.1016/j.anndiagpath.2025.152531.
2
Comprehensive Next Generation Sequencing Reveals that Purported Primary Squamous Cell Carcinomas of the Parotid Gland are Genetically Heterogeneous.全面下一代测序揭示,所谓的腮腺原发性鳞状细胞癌在遗传上具有异质性。
Head Neck Pathol. 2024 Oct 17;18(1):106. doi: 10.1007/s12105-024-01714-6.
3
Keratocystoma: A Distinctive Salivary Gland Neoplasm Characterized by RUNX2 Rearrangements.角化囊肿:一种具有 RUNX2 重排特征的独特唾液腺肿瘤。
Am J Surg Pathol. 2024 Mar 1;48(3):317-328. doi: 10.1097/PAS.0000000000002169. Epub 2023 Dec 12.
4
Methylation Status of the Telomerase Reverse Transcriptase Promoter in Parotid Tumours and Adjacent Parotid Gland Tissue: A Pilot Study on the Implications for Recurrence and Development of Malignancy.腮腺肿瘤及腮腺腺组织中端粒酶逆转录酶启动子的甲基化状态:关于对肿瘤复发及恶性进展影响的初步研究
Curr Oncol. 2025 May 28;32(6):312. doi: 10.3390/curroncol32060312.
5
[Salivary carcinoma showing thymus-like differentiation: clinicopathological analysis of 7 cases].[具有胸腺样分化的涎腺癌:7例临床病理分析]
Zhonghua Kou Qiang Yi Xue Za Zhi. 2024 May 9;59(5):479-485. doi: 10.3760/cma.j.cn112144-20231211-00290.
6
Evaluation of Inflammatory Biomarkers in Parotid Tumors.腮腺肿瘤中炎症生物标志物的评估
Med Sci Monit. 2025 Aug 17;31:e947334. doi: 10.12659/MSM.947334.
7
Head and neck squamous cell carcinomas of unknown primary: Can ancillary studies help identify more primary tumor sites?头颈部不明原发灶鳞状细胞癌:辅助检查能帮助确定更多原发灶部位吗?
Exp Mol Pathol. 2024 Aug;138:104915. doi: 10.1016/j.yexmp.2024.104915. Epub 2024 Jul 3.
8
Expression of CD5 in salivary gland tumors: an ancillary marker for carcinoma showing thymus-like differentiation (CASTLE) of the major salivary gland.CD5在涎腺肿瘤中的表达:大涎腺胸腺样分化癌(CASTLE)的辅助标志物
Virchows Arch. 2024 Jun;484(6):945-950. doi: 10.1007/s00428-023-03701-8. Epub 2023 Nov 13.
9
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
10
Reticular and Myxoid Variant of EBV-positive Nasopharyngeal Carcinoma Mimicking Salivary Gland Tumors: A Case Series.模仿涎腺肿瘤的EB病毒阳性鼻咽癌的网状和黏液样变体:病例系列
Head Neck Pathol. 2025 Jul 14;19(1):87. doi: 10.1007/s12105-025-01825-8.